ERBB2 and breast carcinoma: On the other hand, a placebo-controlled trial including 468 women with breast cancer receiving combined treatment with anthracyclines and anti-HER2, lisinopril, or carvedilol exhibited reduced events rate (37% and 31%, respectively, compared to 47% in patients receiving placebo).